FDA, EMA Approve Setmelanotide for Patients 4+ After Trial Cut BMI 16.5%
Updated
Updated · The ASCO Post · Jul 15
FDA, EMA Approve Setmelanotide for Patients 4+ After Trial Cut BMI 16.5%
3 articles · Updated · The ASCO Post · Jul 15
Summary
Setmelanotide won an expanded U.S. and EU indication for chronic weight management in adults and children aged 4 and older with acquired hypothalamic obesity.
In the 120-patient phase III TRANSCEND trial, BMI fell 16.5% over 52 weeks with setmelanotide versus a 3.3% increase with placebo, while hunger scores also improved significantly.
The once-daily 1.5-3.0 mg injectable was tested in patients with obesity linked to hypothalamic tumors, lesions or injury, a common long-term complication after Craniopharyngioma treatment.
Safety remained a tradeoff: all treated patients had adverse events, serious events occurred in 28% versus 8% on placebo, and common side effects included hyperpigmentation, nausea, vomiting and headache.
The approvals mark the first authorized therapy for this rare survivorship disorder, shifting oncology care beyond tumor control toward chronic treatment-related complications.
This drug targets a specific brain pathway. Could it be the key to treating more common forms of obesity?
With a $440,000 price tag, will this breakthrough obesity drug remain out of reach for most families?
Beyond weight loss, what are the long-term effects of altering a key hunger pathway in the brain?
Landmark FDA Approval: Setmelanotide Delivers 16.5% BMI Reduction in Acquired Hypothalamic Obesity
Overview
In March 2026, the FDA approved setmelanotide (IMCIVREE®) as the first targeted therapy for acquired hypothalamic obesity (HO) in adults and children aged 4 and older. This approval addresses a critical unmet need for patients with HO, a condition caused by damage to the hypothalamus that leads to severe, hard-to-control weight gain. The decision was based on strong clinical evidence from the Phase 3 TRANSCEND trial, where setmelanotide showed significant benefits, including a 16.5% average reduction in BMI and a high rate of meaningful weight loss compared to placebo, offering new hope for those affected by this challenging disorder.